Using the ISRCTN registry to track transparency
The ISRCTN registry wants to encourage trialists to follow research openness and transparency recommendations.
Registry records now display green badges to highlight prospective registration, regular updating of ongoing records and posting protocols, statistical analysis plans (SAPs), data links and results to the record. The BEEP trial is an example that has several of the green badges.
The transparency tracker provides a visual display of the transparency achieved by a set of records, found by a search of the registry. The first stage of this is to track ‘Study results reporting’ for studies that have been completed. Further charts will be added in the future, based on the transparency badges shown on each record. For any search click on 'view in tracker' to view the results in the transparency tracker.
Do you think these new features are useful? We are keen to know what you think! Please complete our feedback form.
The ISRCTN registry is a primary clinical trial registry recognised by WHO and ICMJE that accepts all clinical research studies (whether proposed, ongoing or completed), providing content validation and curation and the unique identification number necessary for publication. All study records in the database are freely accessible and searchable.
ISRCTN supports transparency in clinical research, helps reduce selective reporting of results and ensures an unbiased and complete evidence base.
ISRCTN accepts all studies involving human subjects or populations with outcome measures assessing effects on human health and well-being, including studies in healthcare, social care, education, workplace safety and economic development. The registry welcomes submissions in English from any location. Studies should ideally be registered prospectively (before recruitment starts). ISRCTN also accepts studies registered retrospectively once they are underway or after completion.
The effect of moringa oleifera leaf extract on the inflammation status of breast cancer patients receiving aromatase inhibitor therapy
Comparison of drug-eluting and plain balloon angioplasty in the treatment of stenosis of vascular access for dialysis
Clinical study to assess the safety and efficacy of Lanluma V in the treatment of mid-face volume deficit, nasolabial folds, jawline ptosis and temporal hollowing
.png){kind=spacer}
.png){kind=spacer}
.jpg){kind=spacer}
